CYT 005 AllQbG10

Drug Profile

CYT 005 AllQbG10

Alternative Names: CYT003-QbG10 + approved allergan extract; CYT003-QbG10 combination vaccine - Cytos Biotechnology; CYT005-AllQbG10

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Class Allergy immunotherapies; Antiallergics; Virus-like particle vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Allergic asthma; Allergic conjunctivitis; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 10 Jul 2008 Efficacy and adverse events data from a Phase-II trial in Perennial allergic rhinitis released by Cytos Biotechnology
  • 29 Nov 2007 Cytos Biotechnology initiates enrolment in a phase II trial for perennial allergic rhinitis
  • 17 May 2007 Results from a phase IIa clinical trial in patients with allergic rhinitis have been added to the adverse events and Obstructive Airways Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top